(MedPage Today) — In an analysis of Medicare’s top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no added benefit.
In 2022, Medicare…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114981
Author :
Publish date : 2025-04-04 21:02:00
Copyright for syndicated content belongs to the linked Source.
